News & Trends - Pharmaceuticals
Pfizer files lawsuit to cease sale of biosimilar
Pharma News: Pfizer has filed Federal Court proceedings to halt the sale of a drug that is a biosimilar to the company’s rheumatoid arthritis medication.
The lawsuit against Samsung Bioepis, Merck, Sharp & Dohme (MSD), Organon, and Arrotex, seeks to to halt sales of the biosimilar Brenzys which was listed on the Pharmaceutical Benefits Scheme (PBS) in 2017.
In its lawsuit Pfizer claims the drug companies infringed one of its patents relating to Enbrel titled “Production of polypeptides” by agreeing to manufacture and sell Brenzys in Australia.
Pfizer is seeking compensation for financial losses allegedly suffered because of the sale of Brenzys in Australia and court orders barring the sale of the drug until its patent expires in August 2025.
Enbrel (etanercept) brought in around $1.7 billion in revenue for Pfizer from sales outside the USA and Canada in 2021, according to the company’s most recent financial results.
Pfizer strengthens position to ‘win the digital race in pharma’
The Health Industry Hub news and professional development content are copyright protected and access is provided under individual user licenses. For more information, visit https://www.healthindustryhub.com.au/membership/ and T&Cs.
Medical
NSW Health to settle ‘largest’ class action
A class action alleging NSW Health underpaid clinicians has settled after the department agreed to a payout of nearly a […]
MoreNews & Trends - Pharmaceuticals
Lilly’s first-in-class therapy PBS listed for early breast cancer after 15-year gap
Pharma News: Australians diagnosed with early-stage breast cancer, particularly those at high risk of recurrence, will gain access to the […]
MoreNews & Trends - Pharmaceuticals
AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases
Pharma News: AstraZeneca has scored four positive Pharmaceutical Benefits Advisory Committee (PBAC) recommendations following the March meeting. These recommendations, spanning […]
MoreNews & Trends - Pharmaceuticals
PBAC recommendation to reshape prescribing in heart failure
Pharma News: Aligned with the government’s Scope of Practice Review, the Pharmaceutical Benefits Advisory Committee (PBAC) has made a practice-changing […]
More